Literature DB >> 12396836

CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect.

I A Dodi1, F Van Rhee, H C Forde, C Roura-Mir, D Jaraquemada, J M Goldman, J A Madrigal.   

Abstract

BACKGROUND: The ability to generate a GvL response by infusion of donor leukocytes (DL) in patients following relapse after BMT is now well documented and has been demonstrated to be particularly effective in patients with CML.
METHODS: We generated T-cell lines from a patient who was undergoing an active GvL response following withdrawal of immunosuppression for cytogenetic relapse of CML. Cryopreserved pre-transplant leukemic cells were used as stimulators, to generate T-cell lines and oligoclonal lines from the lymphocytes. In total 38 sub-lines were generated from different bulk cultures. The lines were tested for their proliferative and cytotoxic capability to patient pre-transplant leukemic cells, PHA-transformed lymphoblasts, allogeneic CML cells, and autologous and allogeneic B-LCL.
RESULTS: Four of the cloned lines tested recognized the patient's pre-transplant leukemic cells. Specifically, two were both cytotoxic and proliferative in response to patient leukemic cells and two were cytotoxic only. Six clonal lines recognized PHA blasts only and were proliferative; one was specific for PHA blasts and CML cells. The sub-lines were phenotyped for cell-surface markers and all were CD4(+) CD8(-) CD 16/56(-). The proliferative response of the leukemia-specific clonal lines could be blocked with anti-MHC Class II MAbs. DISCUSSION: These data suggest that CD4(+) cells play a crucial role in mediating the GvL effect in CML patients. Our observations can be used to delineate strategies for enhancing and investigating the GvL effect in CML.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396836     DOI: 10.1080/146532402760271145

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  4 in total

1.  Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity.

Authors:  Marieke Griffioen; Edith D van der Meijden; Elisabeth H Slager; M Willy Honders; Caroline E Rutten; Simone A P van Luxemburg-Heijs; Peter A von dem Borne; Johannes J van Rood; Roel Willemze; J H Frederik Falkenburg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-03       Impact factor: 11.205

2.  Development and dynamics of robust T-cell responses to CML under imatinib treatment.

Authors:  Christiane I-U Chen; Holden T Maecker; Peter P Lee
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

Review 3.  Tumor vaccines and beyond.

Authors:  Jan Joseph Melenhorst; Austin John Barrett
Journal:  Cytotherapy       Date:  2010-11-10       Impact factor: 5.414

4.  Tumor protective activity of CD4+ but not of CD8+ T cells in DNA-vaccinated mice challenged with bcr-abl-transformed cells.

Authors:  Martina Petráčková; Vincent Lučanský; Vladimír Vonka
Journal:  Clin Dev Immunol       Date:  2013-11-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.